tirzepatide news 2025 Use of the dual GIP/GLP-1 drug (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort Eli Lilly's Zepbound outperforms Novo

Auburn, Alabama, USA Address correspondence to: Heather P Whitley 4371 Narrow Lane Rd, Suite #100, Montgomery, Alabama 36116, USA Message to Corresponding Author Article ID: 100073Z09HW2023 Introduction: Guidelines recommend preferential use of antihyperglycemic medications with proven cardiovascular benefit for the treatment of patients with type 2 diabetes with established atherosclerotic cardiovascular disease (ASCVD), high risk factors for ASCVD, kidney disease, or heart failure

Circulation 2006;113:1966-73

Presented for research literature review only Nijhoff W et al

Eye injuries potentially linked to Mounjaro have had a serious impact on patients mental and financial health

They might suggest referral to an endocrinologist for comprehensive metabolic assessment, or to a specialist weight management service if obesity is a significant concern

Overview Product Details Refer to individual products for more information